IFFGD/Digestive Health Alliance “Advocacy: Why Do It?” Tweet Chat Event, June 30, 2015

June 29, 2015

IFFGD/the Digestive Health Alliance will be conducting an open Tweet chat on the topic of “Advocacy: Why Do It?” tomorrow, Tuesday, June 30, at 4:30 PM Eastern Time. To see the questions to be discussed and instructions for participating, please click the following link.


This Tweet chat is in preparation for Advocacy Day,  IFFGD/DHA’s annual day encouraging the IBS/functional gastrointestinal disorders community in the U.S. to contact legislators regarding the Functional Gastrointestinal Disorders Research Enhancement Act (currently HR 2311) and other pending bills of interest to our community.  This year’s Advocacy Day will be on July 21, 2015.  More detailed information will be shared on this blog as it becomes available.

As an IBS advocacy and awareness site, IBS Impact encourages all U.S. citizen readers who are available at the above time and have Twitter accounts to consider joining in the discussion.




Interactive Infographic on Evidence-Based Treatments for Irritable Bowel Syndrome (IBS)

June 22, 2015

IBS Impact is primarily an awareness, advocacy and news blog by people with IBS and does not recommend specific treatments, as experiences of individuals. with IBS vary widely, and those decisions are appropriately made in consultation with one’s health care providers. However, the following interactive infographic from the BMJ (formerly the British Medical Journal) is so well done and potentially useful, that it is worth sharing here. Incorporating the Rome III international diagnostic criteria. (Rome IV was completed by a worldwide group of functional GI experts in December 2014 and is expected to be published in gastroenterology journals for use by early to mid-2016), and the symptom subtypes IBS-D (diarrhea predominant), IBS-C (constipation predominant) IBS-M (mixed, formerly IBS-A for alternating), and IBS-U (unsubtyped), the infographic grades the scientific evidence on many different existing treatment types to give users an idea of what the likely options are for a male or female with a given subtype. The link can be accessed below.


This is only intended as a starting point to make readers aware of some treatments with which they may not be familiar. Again, please consult your personal medical professionals.

Representative Carson of Indiana Co-Sponsors HR 2311 for Functional Gastrointestinal and Motility Disorders

June 13, 2015

According to IFFGD/the Digestive Health Alliance and the official Congressional legislative database Congress.gov, Representative André Carson (D-IN-7) has recently signed on as a co-sponsor to the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2015

Representative Carson, who was first elected the House of Representatives in an special election in 2008, is now serving his fourth full term in Congress. He represents Indiana’s 7th District in the central part of the state, which encompasses most of Marion County and the city of Indianapolis.  According to Representative Carson’s official House website, he  has a record of supporting health care and veterans’ issues. As previously discussed on this blog on August 12, 2011 and August 25, 2011, military service members and veterans are at disproportionately high risk for functional gastrointestinal disorders like IBS, which are already very common in the general population. He was also a co-sponsor of HR 842, a previous version of the same bill that did not pass.

If you are a constituent of Representative Carson, please take a few minutes to write or call him with your thanks for his continuing support of the functional gastrointestinal and motility disorders community.

In officially supporting HR 2311, Representative Carson joins Representative F. James Sensenbrenner, Jr. (R-WI-5) , who is the initial sponsor, and was also the initial sponsor of two previous versions beginning in 2011. If you are a constituent of Representative Sensenbrenner, please thank him for his ongoing commitment to the FGIMD Research Enhancement Act as well.

According to the information on Congress.gov, it appears that the bill is currently under consideration in the Subcommittee on Health. Click on the link above if you would like to see a list of its members.

U. S. citizens, if your Member of Congress is not yet a co-sponsor of HR 2311, please see the previous post from May 18, 2015 for links to the bill and more details on how to do so.  Often, it takes multiple attempts to elicit any interest from legislators, so if you do not receive a reply, do not hesitate to try again or to switch contact methods until you attract attention. Keep in mind that your Representative may be different from before because of the 2014 elections, district boundaries that may have been re-drawn, or if you have moved.

Your personal experiences as a person with IBS and/or other functional GI/motility disorders, or as a concerned family member, friend or colleague, are most effective in communicating to legislators and their staff that there are real human beings behind the statistics. However, even general expressions of support are helpful.

HR 2311 is bipartisan legislation (supported by members of both parties) and according to IFFGD discussions with IBS Impact,  is “revenue-neutral,” meaning that there will be no additional taxes or spending added to the current federal deficit if it is enacted. Discretionary funds are available at the National Institutes of Health to be allocated if Congress directs NIH, through this Act, that functional gastrointestinal and motility disorders are a priority. Congress will only do so if we, as a community, are able to show them the importance of the research, education and FDA coordination provided for in HR 2311.

NIH grants funding to researchers throughout the world, not just in the U.S., so in the long run, enactment of this Act may also benefit readers with IBS in other countries. Medical research also sometimes involves multinational teams of scientists, and in any case, study results are usually published globally, adding to the cumulative knowledge worldwide.

It is IBS Impact’s understanding that HR 2311 will not require a debate or vote on the floor of the House of Representatives, and will pass as soon as it reaches 218 sponsor/cosponsors, or a simple majority of the House. In order for this milestone to be accomplished during the current Congress, the 114th,  the necessary number of sponsor/cosponsors must be reached by December 2016. Every two years, the Congressional membership will be different as a result of elections. Thus, if HR 2311 has not passed by that time,  a similar bill will have to be reintroduced and the FGIMD community will have to start the process of gathering co-sponsors anew. This is what occurred with HR 2239 in 2012 and HR 842 in 2014. While it is quite common for legislation of various sorts to take several Congresses to pass, our continuing advocacy now can increase awareness, build momentum and perhaps accelerate passage. It is in our hands.

Check back on this blog or join IBS Impact’s Facebook page or Twitter feed for further updates on HR 2311 as they occur. Links to the social media sites can be found on the right sidebar of the blog.